Latest filing published 27 Jun 2013 for Atossa Therapeutics, INC., €2,131.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -64.6%Entry US$12,825.00 · Close at T+365 US$4,536.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Alexander D. Cross: trading record in brief
Filings by Alexander D. Cross span 3 companies, the busiest being Marina Biotech, Inc., Atossa Therapeutics, Inc. and Ligand Pharmaceuticals Inc. The record holds 5 filings, for trades running from 1 March 2006 to 15 May 2013.
Purchases make up the whole of the open-market record (1 purchase, €2,131). Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 3 share grants and 1 option exercise. So far in 2013, the count stands at 1 purchase and no sales.
The newest entry dates from 27 June 2013: an open-market purchase of €2,131, in Atossa Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Alexander D. Cross
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 500 shares@ US$5.49Common StockSEC:0000904454-13-000742:0Canonical exit: 13 Aug 2013 (T+90)
- 10,000 shares@ US$1.26Nastech Pharmaceutical Company Inc Common StockSEC:0001209191-08-030114:0
- 5,500 shares0Nastech Pharmaceutical Company Inc Common StockSEC:0001209191-07-037362:0
- 5,000 shares0Nastech Pharmaceutical Company Inc Common StockSEC:0001209191-06-036748:0
- 1,841 shares@ US$3.73Common StockSEC:0001247741-06-000014:0
5 of 5 declarations
